Table 1.
The eight studies included in the meta-analysis of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients. RR: response rate, DCR: disease control rate, NR: not reported.
| Study [Reference] | Year of Publication | Country | Number of Patients | RR (%) | DCR (%) |
|---|---|---|---|---|---|
| Nie et al. [18] | 2022 | China | 54 | 1.9 | 75.9 |
| Arrichiello et al. [19] | 2022 | Italy | 31 | 3.2 | 71.0 |
| Martinez-Lago et al. [20] | 2022 | Spain | 35 (31 evaluable for response) |
3.2 | 51.6 |
| Tamaki et al. [21] | 2022 | Japan | 35 | 0 | 54.3 |
| Kamiimabeppu et al. [22] | 2021 | Japan | 94 | 0 | 44.7 |
| Chida et al. [23] | 2021 | Japan | 139 | 5.8 | 64.0 |
| Nose et al. [24] | 2020 | Japan | 32 | NR | NR |
| Fujii et al. [25] | 2020 | Japan | 21 | 0 | 76.2 |